BofA Global Research cuts Supernus Pharmaceuticals price objective to $55 from $60
SUPN•BofA Global Research cut its price objective for Supernus Pharmaceuticals to $55 from $60.
Related News
Penske Automotive Group to be taken private by Penske Corporation and Mitsui
PAG•
PSEG: Truist Securities cuts target price to $78 from $84
PEG•
Kimberly-Clark reaffirms 2026 financial outlook
KMB•
CNX Resources target price cut to $38 from $42 by Mizuho
CNX•
Rocket Pharmaceuticals participates in Chardan’s 10th annual healthcare conference
RCKT•